Elicio Therapeutics (ELTX) Equity Income (2020 - 2022)

Elicio Therapeutics (ELTX) has reported Equity Income for 3 consecutive years, with $9000.0 the latest figure, recorded in Q3 2022.

• For the quarter ending Q3 2022, Equity Income fell 70.97% year-over-year to $9000.0; the trailing twelve-month figure through Mar 2023 stood at $142000.0 (up 192.21% YoY), and the FY2022 full-year result was $151000.0, up 257.29% from the prior year.
• Equity Income fell to $9000.0 in Q3 2022 per ELTX's latest filing, from $133000.0 in the prior quarter.
• Across five years, Equity Income topped out at $133000.0 in Q2 2022 and bottomed at -$172000.0 in Q4 2021.
• Historically, Equity Income has averaged -$1600.0 across 3 years, with a median of $18500.0 in 2020.
• The sharpest annual moves came in 2021 and 2022: Equity Income sank 178.57% in 2021, then surged 704.55% in 2022.
• Over 3 years, Equity Income stood at -$127000.0 in 2020, then plunged by 35.43% to -$172000.0 in 2021, then soared by 105.23% to $9000.0 in 2022.
• According to Business Quant data, Equity Income over the past three periods registered $9000.0, $133000.0, and $9000.0 for Q3 2022, Q2 2022, and Q1 2022 respectively.